Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Here's What Happened

Key Points

• Pharming Group experienced a significant trading volume increase of 21%, with about 8,033 shares traded on Tuesday, pushing the stock price up to $14.42 from a previous close of $13.89.
• The company reported a quarterly earnings per share of $0.06, exceeding analyst expectations, while revenue also surpassed estimates at $93.20 million compared to $70.36 million anticipated.
• An institutional investor, EverSource Wealth Advisors LLC, purchased a new position in Pharming Group, acquiring 2,979 shares valued at approximately $32,000.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 8,033 shares changed hands during trading, an increase of 21% from the previous session's volume of 6,654 shares.The stock last traded at $14.42 and had previously closed at $13.89.

Pharming Group Trading Up 3.9%

The firm has a 50-day moving average price of $12.15 and a 200-day moving average price of $10.42. The stock has a market capitalization of $988.87 million, a PE ratio of -111.03 and a beta of 0.05. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.The company had revenue of $93.20 million during the quarter, compared to analyst estimates of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.